» Articles » PMID: 16982699

Only Akt1 is Required for Proliferation, While Akt2 Promotes Cell Cycle Exit Through P21 Binding

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2006 Sep 20
PMID 16982699
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Protein kinase B (PKB/Akt) is an important modulator of insulin signaling, cell proliferation, and survival. Using small interfering RNA duplexes in nontransformed mammalian cells, we show that only Akt1 is essential for cell proliferation, while Akt2 promotes cell cycle exit. Silencing Akt1 resulted in decreased cyclin A levels and inhibition of S-phase entry, effects not seen with Akt2 knockdown and specifically rescued by microinjection of Akt1, not Akt2. In differentiating myoblasts, Akt2 knockout prevented myoblasts from exiting the cell cycle and showed sustained cyclin A expression. In contrast, overexpression of Akt2 reduced cyclin A and hindered cell cycle progression in M-G1 with increased nuclear p21. p21 is a major target in the differential effects of Akt isoforms, with endogenous Akt2 and not Akt1 binding p21 in the nucleus and increasing its level. Accordingly, Akt2 knockdown cells, and not Akt1 knockdown cells, showed reduced levels of p21. A specific Akt2/p21 interaction can be reproduced in vitro, and the Akt2 binding site on p21 is similar to that in cyclin A spanning T145 to T155, since (i) prior incubation with cyclin A prevents Akt2 binding, (ii) T145 phosphorylation on p21 by Akt1 prevents Akt2 binding, and (iii) binding Akt2 prevents phosphorylation of p21 by Akt1. These data show that specific interaction of the Akt2 isoform with p21 is key to its negative effect on normal cell cycle progression.

Citing Articles

Calorie restriction and rapamycin distinctly mitigate aging-associated protein phosphorylation changes in mouse muscles.

Ataman M, Mittal N, Tintignac L, Schmidt A, Ham D, Gonzalez A Commun Biol. 2024; 7(1):974.

PMID: 39127848 PMC: 11316767. DOI: 10.1038/s42003-024-06679-4.


Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma.

Shi A, Yun F, Shi L, Liu X, Jia Y Ann Med. 2024; 56(1):2329130.

PMID: 38489405 PMC: 10946270. DOI: 10.1080/07853890.2024.2329130.


Differential activation of AKT isoforms by growth factors in human myotubes.

Roberts B, Geddis A, Matheny Jr R Physiol Rep. 2023; 11(20):e15805.

PMID: 37879895 PMC: 10599983. DOI: 10.14814/phy2.15805.


Role of EGFR and FASN in breast cancer progression.

Chaturvedi S, Biswas M, Sadhukhan S, Sonawane A J Cell Commun Signal. 2023; 17(4):1249-1282.

PMID: 37490191 PMC: 10713975. DOI: 10.1007/s12079-023-00771-w.


Interfering with the Ubiquitin-Mediated Regulation of Akt as a Strategy for Cancer Treatment.

Paccosi E, Balzerano A, Proietti-De-Santis L Int J Mol Sci. 2023; 24(3).

PMID: 36769122 PMC: 9917864. DOI: 10.3390/ijms24032809.


References
1.
Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

2.
Yang J, Cron P, Thompson V, Good V, Hess D, Hemmings B . Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell. 2002; 9(6):1227-40. DOI: 10.1016/s1097-2765(02)00550-6. View

3.
Yang J, Cron P, Good V, Thompson V, Hemmings B, Barford D . Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol. 2002; 9(12):940-4. DOI: 10.1038/nsb870. View

4.
Czauderna F, Fechtner M, Aygun H, Arnold W, Klippel A, Giese K . Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res. 2003; 31(2):670-82. PMC: 140507. DOI: 10.1093/nar/gkg141. View

5.
Blagosklonny M . Are p27 and p21 cytoplasmic oncoproteins?. Cell Cycle. 2003; 1(6):391-3. DOI: 10.4161/cc.1.6.262. View